Dataset from A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00007536
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab
versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic
disease-modifying anti-rheumatic drugs (DMARD) naive.
创建时间：
2025-02-22
